Oryzon Genomics S.A.
A clinical-stage biopharma developing epigenetic therapies for cancer and CNS disorders.
ORY | MC
Overview
Corporate Details
- ISIN(s):
- ES0167733015
- LEI:
- 95980063R15RDF29DK13
- Country:
- Spain
- Address:
- Sant Ferran 74, 08940 Cornellà de Llobregat
- Website:
- https://www.oryzon.com/en
- Sector:
- Manufacturing
Description
Oryzon Genomics is a clinical-stage biopharmaceutical company that develops innovative therapeutics based on epigenetics. The company's primary focus is on creating personalized medicines for patients with cancer and central nervous system (CNS) disorders. Utilizing a proprietary epigenetic platform, Oryzon identifies and validates biomarkers and therapeutic targets to advance its pipeline of potential treatments. The company's therapeutic programs aim to address diseases with significant unmet medical needs by regulating gene expression without altering the underlying genetic sequence.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-12-12 00:00 |
ORYZON anuncia los resultados de la votación de su Junta General Extraordinaria…
|
Spanish | 52.4 KB | ||
| 2025-11-10 00:00 |
Convocatoria de la Junta General Extraordinaria de accionistas de Oryzon Genomi…
|
Spanish | 182.7 KB | ||
| 2025-06-27 00:00 |
ORYZON anuncia los resultados de la votación de su Junta General Ordinaria de A…
|
Spanish | 44.3 KB | ||
| 2025-05-26 08:04 |
Convocatoria de la Junta General Ordinaria de accionistas de Oryzon Genomics, S…
|
Spanish | 139.0 KB | ||
| 2025-05-26 00:00 |
Convocatoria de la Junta General Ordinaria de accionistas de Oryzon Genomics, S…
|
Spanish | 139.0 KB | ||
| 2025-05-12 07:52 |
La sociedad remite información sobre los resultados del primer trimestre de 2025
|
Spanish | 370.8 KB | ||
| 2025-05-08 08:06 |
ORYZON recibe una ayuda no reembolsable de 13,26 millones de € para su proyecto…
|
Spanish | 250.1 KB | ||
| 2025-04-29 00:00 |
Motivo de la notificación: Persona con Responsabilidad de Dirección
|
Spanish | 91.4 KB | ||
| 2025-04-25 13:52 |
Se comunica la inscripción en el Registro mercantil de la escritura de ampliaci…
|
Spanish | 202.4 KB | ||
| 2025-04-24 08:13 |
Resultado de la colocación acelerada
|
Spanish | 178.7 KB | ||
| 2025-04-23 18:34 |
Lanzamiento de ampliación de capital acelerada
|
Spanish | 195.2 KB | ||
| 2025-04-23 17:58 |
Lanzamiento de ampliación de capital acelerada
|
Spanish | 195.2 KB | ||
| 2025-02-28 14:54 |
ORYZON anuncia los resultados de la votación de su Junta General Extraordinaria…
|
Spanish | 51.6 KB | ||
| 2025-02-28 00:00 |
ORYZON anuncia los resultados de la votación de su Junta General Extraordinaria…
|
Spanish | 55.0 KB | ||
| 2025-02-27 19:03 |
La Sociedad remite el Informe Anual sobre remuneraciones de los consejeros del …
|
Spanish | 189.1 KB |
Automate Your Workflow. Get a real-time feed of all Oryzon Genomics S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Oryzon Genomics S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Oryzon Genomics S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
